Cargando…

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients

INTRODUCTION: Circulating tumor cells (CTCs) are tumor cells shed from either primary tumors or its metastases that circulate in the peripheral blood of patients with metastatic cancers. The molecular characterization of the CTCs is critical to identifying the key drivers of cancer metastasis and de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandez, Sandra V, Bingham, Catherine, Fittipaldi, Patricia, Austin, Laura, Palazzo, Juan, Palmer, Gary, Alpaugh, Katherine, Cristofanilli, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303125/ https://www.ncbi.nlm.nih.gov/pubmed/25307991 http://dx.doi.org/10.1186/s13058-014-0445-3

Ejemplares similares

Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients
por: Bingham, Catherine, et al.
Publicado: (2017)

Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer
por: Beck, Tim N., et al.
Publicado: (2019)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
por: Luo, Yanli, et al.
Publicado: (2018)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

TP53 structural variants in metastatic prostatic carcinoma
por: Sirohi, Deepika, et al.
Publicado: (2019)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma
por: Xiao, Wenjing, et al.
Publicado: (2018)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Circulating tumor cells in non-metastatic triple-negative breast cancer
por: Karhade, Mandar, et al.
Publicado: (2014)

EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells
por: Mu, Zhaomei, et al.
Publicado: (2013)

ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer
por: Li, Dong, et al.
Publicado: (2023)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
por: Adams, Daniel L., et al.
Publicado: (2016)

Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling
por: Horigome, Eisuke, et al.
Publicado: (2018)

Germline TP53 and MSH6 mutations implicated in sporadic triple-negative breast cancer (TNBC): a preliminary study
por: Yi, Dandan, et al.
Publicado: (2019)

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and TP53 Mutation Status in Triple-Negative Cases
por: Sadzeviciene, Ieva, et al.
Publicado: (2022)

380 The kinesin-like protein Kif11 is essential for the survival of TP53 mutant triple-negative breast cancer cells
por: Lanier, Amanda, et al.
Publicado: (2023)

Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
por: Fernandez, Sandra V., et al.
Publicado: (2020)

Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer
por: Zhang, Wensheng, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

TP 53 status and estrogen receptor-beta in triple negative breast cancer management in Africa: Time to rethink regime management of triple negative breast cancer and save more lives in Nigeria
por: Nzegwu, Martin Arinzechukwu, et al.
Publicado: (2021)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report
por: Chen, Dongmei, et al.
Publicado: (2022)

Limited importance of the dominant-negative effect of TP53 missense mutations
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2011)

The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
por: Ruijs, Marielle WG, et al.
Publicado: (2009)

Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer
por: Mu, Zhaomei, et al.
Publicado: (2016)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome
por: Raghavakaimal, Ashvathi, et al.
Publicado: (2022)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
por: Zhou, Jie, et al.
Publicado: (2022)

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
por: Kim, Ji‐Yeon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qdivglosahfgs9hs27kvcb1qh2